Cell-Based Identification of New IDO1 Modulator Chemotypes

Area of Science:

• Biochemistry
• Immunology
• Medicinal Chemistry

Background:

• Indoleamine-2,3-dioxygenase (IDO1) is an enzyme that promotes cancer immune escape.
• Inhibiting IDO1 is a promising strategy for cancer immunotherapy.
• Monitoring IDO1 activity in cells is crucial for developing effective inhibitors.

Purpose of the Study:

• To develop a high-throughput, fluorescence-based assay for detecting kynurenine in cells.
• To screen a large compound library for novel IDO1 modulators.
• To identify new chemotypes and mechanisms of action for IDO1 inhibition.

Main Methods:

• Development of a robust, cell-based fluorescence assay to measure kynurenine production.
• High-throughput screening of approximately 150,000 compounds.
• Characterization of identified IDO1 modulators, including their binding to apo-IDO1.

Main Results:

• Discovery of unprecedented, potent IDO1 modulators with diverse mechanisms of action.
• Identification of modulators that inhibit IDO1 directly, regulate its expression, or affect heme synthesis.
• Identification of three chemotypes that bind to apo-IDO1 and compete with the heme cofactor.

Conclusions:

• The developed cell-based assay is a valuable tool for IDO1 inhibitor discovery.
• Novel IDO1 modulators with distinct mechanisms offer new avenues for immuno-oncology drug development.
• This technology provides new opportunities for medicinal chemistry in cancer treatment.